1. TransMedics will release Q2 2025 financial results on July 30, 2025. 2. A conference call will follow the financial results announcement. 3. TransMedics focuses on organ transplant technology for improving organ viability. 4. The company is a leader in portable organ assessment and preservation.
The upcoming results may not significantly affect investor confidence or market trends. However, historical earnings announcements often lead to volatility but not always in the same direction.
The announcement, while routine, begins to shape expectations for TransMedics' performance in the competitive organ transplant market.
The financial results release will have immediate effects on stock price, but long-term trends depend on overall business performance.
ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Brian Johnston
Laine Morgan
332-895-3222
[email protected]
SOURCE TransMedics Group, Inc.